SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine

BACKGROUND: Various studies indicated blunted humoral responses to COVID-19 mRNA and viral vector vaccines among people with multiple sclerosis (pwMS) on sphingosine 1-phosphate receptor (S1PR) modulators and anti-CD20 therapies (aCD20); however, limited evidence was found regarding SARS-CoV-2 serol...

Descripción completa

Detalles Bibliográficos
Autores principales: Etemadifar, Masoud, Sedaghat, Nahad, Nouri, Hosein, Lotfi, Noushin, Chitsaz, Ahmad, Khorvash, Reza, Zolfaghari, Hamed, Ghasemi Movaghar, Alireza, Pourabbas, Mohammad, Salari, Mehri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607735/
https://www.ncbi.nlm.nih.gov/pubmed/34875487
http://dx.doi.org/10.1016/j.msard.2021.103417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607735/
https://www.ncbi.nlm.nih.gov/pubmed/34875487
http://dx.doi.org/10.1016/j.msard.2021.103417

Ejemplares similares